Pneumonitis Risk in NSCLC Remains Uncertain, Obesity May Be Predictor
Outcomes were evaluated among veterans treated for non–small cell lung cancer (NSCLC) from 2017 to 2020 with durvalumab, a PD-L1 inhibitor.
Source: ajmc.com
Page 12 - Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nsclc Today - Breaking & Trending Today
FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC
The FDA granted priority review to a sBLA seeking the approval of alectinib as adjuvant treatment after surgery for early-stage ALK-positive NSCLC.
Source: onclive.com
Biomarker Identification Drives Research and Drug Development in NSCLC and SCLC
Ranee Mehra, MD, and colleagues detail treatment updates across lung cancer subtypes, including navigating the array of available ALK inhibitors in NSCLC.
Source: onclive.com
Toxicity Linked to Longer Survival in Patients With NSCLC
A new cohort study shows that some immune-related adverse events are linked to longer survival in patients with NSCLC treated with immunotherapy.
Source: medscape.com
EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights
Edgardo Santos, MD, FACP, FCCP, offers expert insights into the squamous subgroup analysis of EMPOWER-Lung1 and 3, shedding light on the implications of these data for the treatment of individuals with squamous non-small cell lung cancer (NSCLC).
Source: onclive.com